Becton Dickinson Receives the US FDA’s EUA for its Third Point-Of-Care SARS-CoV-2 Diagnostic Test to Detect COVID-19

 Becton Dickinson Receives the US FDA’s EUA for its Third Point-Of-Care SARS-CoV-2 Diagnostic Test to Detect COVID-19

Shots:

  • The US FDA has granted Emergency Use Authorization (EUA) for its rapid point-of-care BD Veritor SARS-CoV-2 Assay which allows the result in 15 mins evaluated in 20 sites across the US with 84% sensitivity and 100% specificity. Additionally, BD plans for increasing capacity to produce 2M tests per week by the end of September with an expected production of up to 10M tests from July through September
  • The BD Veritor System is a one-button functionality with workflow flexibility offering real-time data with BD Synapsys informatics solution used in 25000+ hospitals, clinician offices, care centers and pharmacies in all 50 the US states  
  • BD Veritor SARS-CoV-2 Assay is the third test added to the portfolio of two with EUAs and two with the CE mark in use with the BD MAX Molecular System. Additionally, the company plans for 510(k) clearance for the assay and interested US customers in BD diagnostic solutions contact IDS.COVIDtests@bd.com

Click here to read full press release/ article | Ref: Becton Dickinson | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post